The Precipio second quarter 2024 shareholder update conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements, as these statements are based upon our current expectations, forecasts, and assumptions and are subject to significant risks and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue, or the negative of these terms, or other words or terms of similar meaning. Risks and uncertainties that could cause our actual results to differ materially from these, those set forth in any forward-looking statements include, but are not limited to, the matters listed under Risk Factors in our Annual Report on Form 10-K for the year ended December 31st, 2023, which is on file with the Securities and Exchange Commission, as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. Statements and information, including forward-looking statements, speak only to the date they are provided, unless an earlier date is indicated. We do not undertake any obligation to publicly update any statements or information, including forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Now, let me turn the floor over to Ilan Danieli, Precipio's CEO. Please go ahead. Thank you very much. Good afternoon, everyone, and thank you for joining our 2024 Q2 shareholder update call. I'd like to thank those of you who submitted questions. As always, I will try my best to address them during this call. As you saw in our recent 10-K filing last week, we are on track to hit our goals for this year. Revenue continued to grow, with the pathology division reaching breakeven at the end of Q2. I'm pleased to inform that so far, we've continued on that track, and in Q3 to date, we are exceeding our breakeven target for the pathology division. We have a solid team, our existing customer base is stable, and our new customer base is growing. We will continue to build an excess cushion of revenue to ensure that the pathology division fulfills its purpose within the company's strategy, which is to serve as a cost-neutral, rapid R&D facility to develop our products, while itself remaining profitable and generating cash to the company. In the products division, we also continue to make progress towards breakeven. In the past, we discussed three large customers that we are working with to go live with our HemeScreen program, and when they do, this division will reach its target. Once we reach breakeven for this division, the entire company will be profitable. In this quarter, two of the three customers have gone live and are growing their volume and adding panels. We expect that by the end of this quarter, they will be in full-fledged activity, which means that going into Q4, we can expect that these customers will contribute to an increase in revenue. The third customer is still in progress and is working through several operational issues before they go live. We are working diligently with them in order to ensure that this third customer will also be fully onboarded too. Of course, we have quite a few other small and mid-sized customers that are either in the process or have gone live during Q2, and we're starting to see their orders come in. Each of these customers forms yet another building block of recurring revenue to the company and brings us closer to hitting our breakeven targets. In the previous shareholder call, I commented on our work with the distributors to revamp the working relationship with them and identify the recipe for success. We worked closely with the management teams of our distributors to formulate a plan, and in Q2, we began to put it in place. We've begun to see the fruits of the new recipe with our distributors in the form of better customer targeting, more introductions and conversations with the right decision makers, and progress towards bringing those customers on board. Some of you have asked, "Why are we spending time and effort with distributors when so far we've been more successful with our direct sales approach?" The reason is, we believe that distributors are the key to scaling up the business. Although for now we're focused on reaching profitability, the total market just for the HemeScreen product is approximately $400 million annually in the U.S. and a similar amount worldwide. We are not even at 1% of that market share, and the way to scale up is through our distributors. Our U.S. distributors, Cardinal Health, Thermo Fisher, and McKesson, collectively employ hundreds of sales reps that have spent years building relationships with customers. They know who the decision makers are within those customers and what is the process and best approach to sell product into them, and most importantly, they have access to these customers. It's no secret that in the healthcare field, leveraging a distribution network has the potential for business to scale up far more efficiently and rapidly by tapping into those established channels, expertise, and resources, and enabling faster market penetration and broader reach, as opposed to attempting to go only direct. Therefore, as we establish our presence in the market and build our customer base, we believe that the way to scale up this business and capture significant market share is through our distribution channels. But like with any other partner you work with, it takes time to build successful relationships. We continue to work closely with our distributors to refine the program and messaging and to build relationships which will help foster growth in our sales. Next, I'd like to discuss our cash position. As you saw in Q2, we actually had an increase in cash of approximately $300,000. While this is terrific news, and yes, we are getting close, this is not to be confused with us being profitable just yet. We're still dealing with the aftermath issues from the Change Healthcare hack earlier this year, including fund transfers from Change Healthcare, delayed payments from Medicare and other payers, and we've not yet returned to a steady state of billing and collection. However, we believe that the situation is getting much better, and we are moving towards returning to that stable situation we had prior to the hack. From an operational perspective, we are reducing our cash burn and we're and moving towards breakeven. And as we stand today, we believe that we have sufficient cash to meet our obligations and reach that target of profitability by year-end. You've heard me say this many times: It's time for our company to be financially independent and stand on our own two feet. I still believe that we have sufficient resources to reach that point. Next, I'd like to provide an update on our process with the FDA. We submitted to the FDA the required materials for our pre-submission meeting. Those materials have been accepted, and the meeting with the FDA has been scheduled for later this year. We feel that we are in a good position to submit our application to the FDA soon after the meeting, and we hope to receive approval sometime in 2025. We're still seeing in the market significant confusion around the FDA ruling, both from customers who are not sure how to handle the situation and from manufacturers who have not yet decided what they're going to do. We actually view this as a competitive advantage for us and believe that this ruling will weed out quite a few of the competitors. Once received, we believe having an FDA seal of approval on our product will help us gain further market share and provide additional credibility to our products. Finally, I'd like to comment on our share price performance. For the recent months, we've been hovering around the $5-$6 range, and it seems that the share price is at least stable and no longer suffers from the tremendous shorting pressures we used to experience. So that's a good thing. Having said that, if you take our Q2 revenues of $4.4 million, which translates into about $17.5 million annualized run rate, this still equates to a market cap of less than 0.5 times our revenue multiple. Looking at comparables in the market and at the company situation, this doesn't seem to us, and to many outside observers, as a reasonable multiple. So we ask ourselves, what's keeping the stock price at its current place? We consider two factors. The first is that the market is still skeptical of our performance, our revenue growth, and our cash needs, and believes we will still need to raise diluted capital. As we continue on track, the next couple of quarters will hopefully dissolve this notion entirely. The second factor is that the company, and me personally, have not spent any significant time and resources on the IR side of this investor relations. All companies, and especially microcap companies such as ours, battle for investor attention and work to build their presence and brand within the investment community. For the past few years, we've spent our effort building our business and have spent very little time on the IR side. Our plan is that upon achieving our goals by the end of this year and demonstrating to the market that we are indeed a profitable company with a growing customer base, with a backlog and pipeline of new business and a roadmap to scale this business through our distributors, then we have a story that we can go out and share with the investor community. A combination of presence at investor conferences and meetings, coupled with work on the digital side, can help build a substantial audience of people who will potentially follow the company. With continuous performance and results, that should translate into an increase in trading volume and presumably a correction of our company's revenue multiple from its current zero point five times revenue to a number that is more in line with industry comparable. Needless to say, our company is working hard to achieve its business results, and the impact of the business results on the company's share price is a key focal point at all times. In summary, we're in a good place, and I'm really excited to continue with the momentum we have. With the pathology division stabilized and exceeding its breakeven targets, and products division heading in that direction, we have enough gas in the tank to get there. I think the hard work will pay off when our company reaches its goals for 2024. Furthermore, as you can see, we're also thinking about our strategy for 2025 in terms of scaling up the product business as well as rekindling our IR strategy, so that we can translate all the good work that our team has accomplished into shareholder value. I'd like to thank you for your support, and I look forward to connecting with you on our next quarterly call. Thank you, and have a nice day. Ladies and gentlemen, the conference has now concluded. We do thank you for attending today's presentation. You may now disconnect your lines.